To explore whether immunotherapy could improve the efficacy of anlotinb, we compared the efficacy of anlotinib plus immunotherapy (anti-PD-1 or PD-L1 antibodies) with anlotinib alone in NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.